Evans Terry L 4

What Happened Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals (FENC), received 168 shares on 2026-05-31 as a release of previously awarded restricted stock. The shares were acquired at $0.00 (no cash consideration), so the reported transaction value is $0. This is not a purchase or sale — it reflects vesting/release of an award.

Key Details

• Transaction date: 2026-05-31; Filing date: 2026-06-01 (filed the next day, within the usual Form 4 timing requirements).
• Transaction type/code: Award/Grant or other acquisition (A).
• Shares involved: 168 shares acquired at $0.00; total reported $0.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote: "Represents shares released from restriction from shares awarded 3/28/2025."
• No indication of a contemporaneous sale or tax-withholding reported in this filing.

Context This transaction represents vesting/release of restricted stock previously awarded (a common form of executive compensation) and does not involve the insider buying or selling shares in the market. Such releases are generally administrative and don't necessarily indicate a change in the insider's view of the company. Purchases or open-market sales tend to be more directly informative about insider sentiment.